Comparing NeuroOne Medical Technologies (NASDAQ:NMTC) & Beauty Health (NASDAQ:SKIN) – Defense World
Posted by admin on Aug 7th, 2022
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Rating) and Beauty Health (NASDAQ:SKIN – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.
This table compares NeuroOne Medical Technologies and Beauty Health’s net margins, return on equity and return on assets.
This table compares NeuroOne Medical Technologies and Beauty Health’s revenue, earnings per share and valuation.
NeuroOne Medical Technologies has higher earnings, but lower revenue than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations for NeuroOne Medical Technologies and Beauty Health, as reported by MarketBeat.com.
NeuroOne Medical Technologies currently has a consensus price target of $2.63, suggesting a potential upside of 52.62%. Beauty Health has a consensus price target of $24.75, suggesting a potential upside of 68.71%. Given Beauty Health’s stronger consensus rating and higher probable upside, analysts plainly believe Beauty Health is more favorable than NeuroOne Medical Technologies.
11.2% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 72.0% of Beauty Health shares are owned by institutional investors. 34.3% of Beauty Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NeuroOne Medical Technologies has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Beauty Health has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Beauty Health beats NeuroOne Medical Technologies on 10 of the 14 factors compared between the two stocks.
(Get Rating)
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
(Get Rating)
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for NeuroOne Medical Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
Maxim Group Reiterates “Buy” Rating for Perficient (NASDAQ:PRFT)